Get the Stockscreener App
7.52
0.53%
-0.04
After Hours:
7.51
-0.010
-0.13%
Corbus Pharmaceuticals Holdings Inc stock is traded at $7.52, with a volume of 100.37K.
It is down -0.53% in the last 24 hours and down -9.62% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$7.56
Open:
$7.54
24h Volume:
100.37K
Relative Volume:
0.34
Market Cap:
$132.00M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.6103
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
-5.05%
1M Performance:
-9.62%
6M Performance:
-18.70%
1Y Performance:
-11.63%
1-Day Range:
$7.235
$7.6116
1-Week Range:
$7.235
$8.08
52-Week Range:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
7.52 | 132.70M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Decliners Report: What is Corbus Pharmaceuticals Holdings Incs revenue forecastJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - Bitget
Corbus Pharmaceuticals to Present at 36th Annual Oppenheimer Healthcare Life Sciences Conference - Quiver Quantitative
Can Corbus Pharmaceuticals Holdings Inc. maintain its current growth rateQuarterly Earnings Summary & AI Driven Stock Price Forecasts - mfd.ru
Stock Recap: What is the cash position of Corbus Pharmaceuticals Holdings IncQuarterly Profit Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Published on: 2026-02-11 16:50:32 - mfd.ru
Should I hold or sell Corbus Pharmaceuticals Holdings Inc. stock in 2025July 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Published on: 2026-02-08 12:15:37 - baoquankhu1.vn
Responsive Playbooks and the CRBP Inflection - Stock Traders Daily
Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms - Seeking Alpha
Forecast Cut: What dividend growth rate does Corbus Pharmaceuticals Holdings Inc offerJuly 2025 Intraday Action & Weekly Setup with ROI Potential - baoquankhu1.vn
Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis - MarketBeat
Dominic Smethurst Sells 3,285 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) COO Sells $19,537.35 in Stock - MarketBeat
Signal Recap: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issues2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Corbus Pharmaceuticals Completes $75 Million Public Offering - MSN
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
While institutions invested in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Understanding the Setup: (CRBP) and Scalable Risk - Stock Traders Daily
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Aberdeen Group plc Expands Holdings in Corbus Pharmaceuticals Ho - GuruFocus
Can Corbus Pharmaceuticals Holdings Inc. stock sustain institutional interestLong Setup & Daily Price Action Insights - bollywoodhelpline.com
Revenue Check: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issues2025 Geopolitical Influence & Accurate Intraday Trading Signals - baoquankhu1.vn
CRBP: CRB-701 and CRB-913 advance with strong data, regulatory clarity, and funding into 2028 - TradingView
Corbus Pharmaceuticals surges on CRB-913 trial success - Intellectia AI
Corbus declines following early-stage results on oral obesity asset CRB-913 - MSN
Market Wrap: Why Corbus Pharmaceuticals Holdings Inc stock could be next big winnerCPI Data & AI Enhanced Trading Signals - Bộ Nội Vụ
Corbus Updates Corporate Outlook, Highlights Diversified 2026 Pipeline - TipRanks
Published on: 2026-01-12 10:26:56 - Улправда
Corbus presents new cancer drug study at ASCO GU - MSN
Why Corbus Pharmaceuticals Holdings Inc. stock could outperform in 2025Gap Up & Weekly Top Performers Watchlists - Улправда
The 3 Best Cannabis Stocks to Buy for 2026 - Yahoo Finance
Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentumMarket Trend Review & Weekly Top Gainers Trade List - Улправда
Will Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain dividend payoutsJuly 2025 Retail & Free Verified High Yield Trade Plans - Улправда
Aug Outlook: Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentum - Улправда
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
News | postregister.comCorbus Pharmaceuticals Holdings, Inc.Common Stock (Nasdaq:CRBP) Detailed Stock Data - FinancialContent
Revenue per share of Corbus Pharmaceuticals Holdings Inc – LSE:0SZI - TradingView — Track All Markets
J.P. Morgan Healthcare Conference - marketscreener.com
Corbus Pharmaceuticals to Present Corporate Overview at the 2026 Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corbus Pharmaceuticals shares rise on encouraging safety results for experimental obesity drug - MSN
While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smethurst Dominic | Chief Medical Officer |
Feb 03 '26 |
Sale |
8.09 |
3,285 |
26,575 |
95,887 |
| Hodgson Ian | Chief Operating Officer |
Feb 03 '26 |
Sale |
8.09 |
2,415 |
19,537 |
51,927 |
| Cormorant Asset Management, LP | 10% Owner |
Dec 11 '25 |
Sale |
11.46 |
30,029 |
344,012 |
2,344,971 |
| Cohen Yuval | Chief Executive Officer |
Oct 24 '25 |
Option Exercise |
4.26 |
18,660 |
79,492 |
156,847 |
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Option Exercise |
4.26 |
8,973 |
38,225 |
147,160 |
| Cohen Yuval | Chief Executive Officer |
Oct 24 '25 |
Sale |
17.01 |
18,660 |
317,407 |
138,187 |
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Sale |
17.14 |
8,973 |
153,797 |
138,187 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Option Exercise |
4.26 |
12,981 |
55,299 |
86,294 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Sale |
17.02 |
12,981 |
220,937 |
73,313 |
4.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):